These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32815024)

  • 1. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
    Lazzerini L; Jöhrens K; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin as a target for cervical cancer therapy.
    Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
    Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
    Mansfield AS; Vivien Yin J; Bradbury P; Kwiatkowski DJ; Patel S; Bazhenova LA; Forde P; Lou Y; Dizona P; Villaruz LC; Arnold SM; Khalil M; Kindler HL; Koczywas M; Pacheco J; Rolfo C; Xia B; Mikula E; Chen L; Patel K; Smith KER; Cao L; Shapiro G; Costello BA; Adjei A; Sharon E; Moscow JA; Zamboni W; Hassan R
    Lung Cancer; 2024 Sep; 195():107928. PubMed ID: 39197359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
    Quanz M; Hagemann UB; Zitzmann-Kolbe S; Stelte-Ludwig B; Golfier S; Elbi C; Mumberg D; Ziegelbauer K; Schatz CA
    Oncotarget; 2018 Sep; 9(75):34103-34121. PubMed ID: 30344925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Kindler HL; Novello S; Bearz A; Ceresoli GL; Aerts JGJV; Spicer J; Taylor P; Nackaerts K; Greystoke A; Jennens R; Calabrò L; Burgers JA; Santoro A; Cedrés S; Serwatowski P; Ponce S; Van Meerbeeck JP; Nowak AK; Blumenschein G; Siegel JM; Kasten L; Köchert K; Walter AO; Childs BH; Elbi C; Hassan R; Fennell DA
    Lancet Oncol; 2022 Apr; 23(4):540-552. PubMed ID: 35358455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
    J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
    Chen V; Umemura S; Han Y; Raman R; Tucker R; Chahine J; Kim IK; Schatz C; Zitzmann-Kolbe S; Sommer A; Onda M; Lee T; He Y; Giaccone G
    Br J Cancer; 2022 Mar; 126(5):754-763. PubMed ID: 34876673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer.
    Mauricio D; Harold J; Tymon-Rosario JR; Zeybek B; Santin AD
    Expert Opin Biol Ther; 2021 Aug; 21(8):1087-1096. PubMed ID: 33356644
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
    Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
    Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates in gynecologic malignancies.
    Lee EK; Liu JF
    Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D; Cristea M
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.
    Chu Q
    Curr Oncol Rep; 2023 Apr; 25(4):309-323. PubMed ID: 36763234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.
    Zhao XY; Subramanyam B; Sarapa N; Golfier S; Dinter H
    Clin Cancer Drugs; 2016 Oct; 3(2):76-86. PubMed ID: 27853672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
    ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
    Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.